Samuel J. Reich

Samuel J. Reich

Chief Executive OfficeratSAB Biotherapeutics· In proxies 2022–2025

Pay in FY2025+265% from the year before · SAB Biotherapeutics stock -1.4% the same year

Samuel J. Reich was paid $9.4M in FY2025 (Dec), up 265%. SAB Biotherapeutics stock fell 1.4% that year.

Pay$100 in the stock at the end of FY21 → $5
Pay is from the Summary Compensation Table of each SAB Biotherapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. SAB BiotherapeuticsPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role -96%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?